Influence of histone deacetylase 1 on insulin resistance in a cell model of nonalcoholic fatty liver disease

Heng ZHU; Weizong KONG; Guiqun HUANG; Yu BAI; Yingchun WANG

doi:10.3969/j.issn.1001-5256.2022.09.013

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2010-2015

PDF( 2418 KB)

Influence of histone deacetylase 1 on insulin resistance in a cell model of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.09.013

1.
Second Department of Gastroenterology, Zhongshan Hospital Affiliated to Dalian University, Dalian, Liaoning 116001, China
2.
Dalian University, Dalian, Liaoning 116001, China

Research funding:

Special Fund for Doctoral Startup of Dalian University (20181QL005)

More Information

Corresponding author: WANG Yingchun, wych_1648@126.com(ORCID: 0000-0002-6664-4947)
Received Date: 2022-01-15
Accepted Date: 2022-02-24
Published Date: 2022-09-20

Abstract

Abstract

Objective To investigate the promoting effect of histone deacetylase 1 (HDAC1) expression on insulin resistance (IR) in nonalcoholic fatty liver disease (NAFLD) cells by establishing an HepG2 cell model of high fat-induced NAFLD. Methods HepG2 cells were divided into control group, model group (OA), and inhibitor group (OA+pyroxamide [an HDAC1 inhibitor]). CCK-8 assay was used to plot the standard growth curve of HepG2 cells and screen out the optimal drug concentration and action time of OA and pyroxamide; oil red O staining was used to compare the accumulation of lipid droplets in cells; an automatic biochemical analyzer was used to analyze the content of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), and total cholesterol (TC) in cells; quantitative real-time PCR and Western blot were used to measure the mRNA and protein expression levels of HDAC1 and insulin receptor substrate-1 (IRS-1) in cells. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results OA treatment at a concentration of 0.25 mmol/L for 24 hours was the optimal concentration and duration of cell modeling, and treatment at a concentration of 20 μmol/L for 24 hours was the optimal administration concentration and duration of pyroxamide. Compared with the control group, the model group had significant increases in the content of ALT, AST, TG, and TC, and compared with the model group, the inhibitor group had significant reductions in the content of ALT, AST, TG, and TC (all P < 0.05). The model group had significantly higher mRNA and protein expression levels of HDAC1 than the control group, while the inhibitor group had significantly lower expression levels than the model group (all P < 0.05); the model group had significantly lower mRNA and protein expression levels of IRS-1 than the control group, while the inhibitor group had significantly higher expression levels than the model group (all P < 0.05). Conclusion HDAC1 participates in the development and progression of NAFLD by inhibiting the expression of IRS-1 molecule and promoting IR, and the HDAC1 inhibitor pyroxamide can exert a protective effect on the liver by alleviating IR.
- Non-Alcoholic Fatty Liver Disease,
- Histone Deacetylase 1,
- Insulin Resistance

FullText(HTML)

References(14)

References

[1]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[2]	WANG YH, GAO Y. Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus[J]. J Jilin Univ(Med Edit), 2020, 286(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634. 王雨涵, 高影. 非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报(医学版), 2020, 286(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
[3]	DAY CP, JAMES OF. Steatohepatitis: a tale of two "hits"?[J]. Gastroenterology, 1998, 114(4): 842-845. DOI: 10.1016/s0016-5085(98)70599-2.
[4]	YANG ZB, PENG H, MA SW. Progress in epigenetics of liver diseases[J]. Chin Hepatol, 2017, 22(5): 381-384. DOI: 10.3969/j.issn.1008-1704.2017.05.002. 杨智彬, 彭惠, 马世武. 肝脏疾病的表观遗传学研究进展[J]. 肝脏, 2017, 22(5): 381-384. DOI: 10.3969/j.issn.1008-1704.2017.05.002.
[5]	CASTELLANO D, RAMOS B, OLIVA W, et al. Genome profiling of H3k4me3 histone modification in human adipose tissue during obesity and insulin resistance[J]. Biomedicines, 2021, 9(10): 1363. DOI: 10.3390/biomedicines9101363.
[6]	FU S, YU M, TAN Y, et al. Role of histone deacetylase on nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(4): 353-361. DOI: 10.1080/17474124.2021.1854089.
[7]	SODUM N, KUMAR G, BOJJA SL, et al. Epigenetics in NAFLD/NASH: Targets and therapy[J]. Pharmacol Res, 2021, 167: 105484. DOI: 10.1016/j.phrs.2021.105484.
[8]	GUO YW, TAO L, LIN XY, et al. Role of histone deacetylase 1 in course of mice NAFLD[J]. J Sun Yat-Sen Univ(Medical Sciences), 2016, 37(6): 840-844. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201606008.htm 郭云蔚, 陶力, 林显艺, 等. 组蛋白去乙酰化酶1在小鼠非酒精性脂肪肝中的表达和作用[J]. 中山大学学报(医学科学版), 2016, 37(6): 840-844. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201606008.htm
[9]	RAJAN PK, UDOH UA, SANABRIA JD, et al. The role of histone acetylation-/methylation-mediated apoptotic gene regulation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(23): 8894. DOI: 10.3390/ijms21238894.
[10]	JAMES DE, STÖCKLI J, BIRNBAUM MJ. The aetiology and molecular landscape of insulin resistance[J]. Nat Rev Mol Cell Biol, 2021, 22(11): 751-771. DOI: 10.1038/s41580-021-00390-6.
[11]	YANG Q, VIJAYAKUMAR A, KAHN BB. Metabolites as regulators of insulin sensitivity and metabolism[J]. Nat Rev Mol Cell Biol, 2018, 19(10): 654-672. DOI: 10.1038/s41580-018-0044-8.
[12]	MAUDE H, SANCHEZ-CABANILLAS C, CEBOLA I. Epigenetics of hepatic insulin resistance[J]. Front Endocrinol (Lausanne), 2021, 12: 681356. DOI: 10.3389/fendo.2021.681356.
[13]	KHAN S, KOMARYA SK, JENA G. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition[J]. Epigenomics, 2017, 9(5): 711-720. DOI: 10.2217/epi-2016-0160.
[14]	KHAN S, KUMAR S, JENA G. Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat[J]. Biochimie, 2016, 125: 42-52. DOI: 10.1016/j.biochi.2016.02.014.

Relative Articles

[1]	Sulian YANG, Rongjie SHI, Lihua LI. Value of Fetuin-A， Fetuin-B， and insulin resistance index in predicting nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(4): 694-699. doi: 10.12449/JCH240409
[2]	Hongliang CUI, Li XU, Tong LU. Association of glucagon-like peptide-1 system with the prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(6): 1406-1410. doi: 10.3969/j.issn.1001-5256.2022.06.039
[3]	Xiaohan YU, Yulu WANG, Xiaoyang XU, Jian PING, Changqing ZHAO. Effect of glucagon-like peptide-1 receptor agonist in treatment of nonalcoholic fatty liver disease and related mechanism[J]. Journal of Clinical Hepatology, 2021, 37(1): 196-199. doi: 10.3969/j.issn.1001-5256.2021.01.043
[4]	Peiyu ZHENG, Xiuqin AN, Jinchun LIU. Role of angiopoietin-like proteins in the development of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2680-2683. doi: 10.3969/j.issn.1001-5256.2021.11.042
[5]	Pinhua LI, Xudong LIU, Lu HUANG, Humin ZHU, Tiexiong WU, Huazhen PANG. Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2558-2561. doi: 10.3969/j.issn.1001-5256.2021.11.015
[6]	Liu ZhiPing, Zhao ZhiWei, Zhang JinHua. Correlation of intestinal flora with serum glucagon-like peptide-1 level in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 136-139. doi: 10.3969/j.issn.1001-5256.2020.01.030
[7]	A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
[8]	Dou AiHua, Hui Wei, Liu Mei, Wei LinLin, Zhao Juan, Ma ChunHua, Zheng XiaoQin, Xiong Fang, Yang Xue, Zhang Mei, Xu Bin. Association between rs2943650 mutation and insulin resistance in patients with chronic liver disease and type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2018, 34(11): 2379-2382. doi: 10.3969/j.issn.1001-5256.2018.11.022
[9]	Yang Shuai, He SongQing. Role of silent information regulator 1 in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(3): 649-652. doi: 10.3969/j.issn.1001-5256.2018.03.047
[10]	Liu DaJi, Chen QingFeng. Pathogenesis of insulin resistance and its impact on antiviral therapy in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1152-1155. doi: 10.3969/j.issn.1001-5256.2017.06.029
[11]	Ding ZhiYong, Bu Le, Lu HongYan, Rao ZhengXuan. Correlation of liver fat content with serum vitamin A level and insulin resistance in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2361-2365. doi: 10.3969/j.issn.1001-5256.2017.12.021
[12]	Zhang QiuNan, Xiao Ying, Miao RuiXin, Zhang YaQing, Zhu Ying. Changes in intestinal flora in nonalcoholic fatty liver disease: their correlation with insulin resistance index,tumor necrosis factor- α,and interleukin- 6[J]. Journal of Clinical Hepatology, 2015, 31(7): 1078-1081. doi: 10.3969/j.issn.1001-5256.2015.07.019
[13]	Ma LiNa, Feng Ming, Zhou YingZhi, Ma Jia, Hao Peng. The relationship between nonalcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2010, 26(2): 173-174+177.
[14]	Yu XiaoHu, Zhu JinShui, Gu GuoMei, Shi JianPing. Clinical effect of oxymatrine combined with metformin on insulin resistance and serum TNF-α in patients with non-alcoholic fatty liver[J]. Journal of Clinical Hepatology, 2007, 23(3): 195-196.
[15]	Zhang FenMing, Gao SuQin, Kong DeZhi. Relationship between nonalcoholic fatty liver disease and insulin resistance in hypertensive patients[J]. Journal of Clinical Hepatology, 2007, 23(4): 277-279.
[16]	Li YuQin, Po YunFeng, Chen ZhaoJie, Ding BaiJing, Tang TongYu, Wang Dan, Gao YanHang, Jin JingLan. Relationship between the levels of serum leptin and insulin resistance in patients with fatty liver[J]. Journal of Clinical Hepatology, 2007, 23(5): 360-361.
[18]	Liang Bing, Chen Xi, Liu ShuangYan, Wang YiGe, An QiuHong. The relationship between non-alcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2006, 22(3): 213-214.
[19]	Huang JiLiang, Wu Fang, Zhang XinRan, Wang DongHua, Zhao RuiZhi. Relationship between tumor necrosis factor-α and lnsulin resistance in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2002, 18(3): 166-167.
[20]	Ma YingJie, Fang LiFeng, Feng SuPing, Jia KeLi, Fu ZhenLie. Obesity and insulin resistance in nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2002, 18(4): 241-242.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 刘克帅，李月，祝佳音，尹强，徐春艳，段行武. 银屑病与非酒精性脂肪性肝病相关性的Meta分析. 皮肤病与性病. 2023(03): 203-208 .
Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(7)

Get Citation

PDF

XML

Article Metrics

Article views (605) PDF downloads(43)

Influence of histone deacetylase 1 on insulin resistance in a cell model of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.09.013

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Influence of histone deacetylase 1 on insulin resistance in a cell model of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.09.013

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content